July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Response to Patching in Amblyopic patients with and without Fusion Maldevelopment Nystagmus
Author Affiliations & Notes
  • Fatema Firoz Ghasia
    Ophthamology and visual science, Cole Eye Institute-Cleveland Clinic, Chagrin Falls, Ohio, United States
  • Aasef Shaikh
    Neurology, Case Western Reserve University, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Fatema Ghasia, None; Aasef Shaikh, None
  • Footnotes
    Support  Fight for Sight
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 213. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Fatema Firoz Ghasia, Aasef Shaikh; Response to Patching in Amblyopic patients with and without Fusion Maldevelopment Nystagmus. Invest. Ophthalmol. Vis. Sci. 2019;60(9):213.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Amblyopia is a neurodevelopmental disorder due to de-correlated binocular input to the visual cortex. The treatment comprises of occlusion of non-amblyopic eye to promote the development of vision in amblyopic eye. Amblyopes who experienced disruption of binocularity during first six months of life develop fusion maldevelopment nystagmus (FMN). The slow phase velocity (SPV) of FMN increases under monocular viewing conditions. Limited studies have shown that full-time occlusion causes a compensatory decrease in SPV over days, thus it was recommended in patients with FMN.

Methods : Amblyopic patients with and without FMN were recruited. Part-time occlusion (2-6 hours/day) was prescribed depending on the severity of amblyopia per the PEDIG studies. We analyzed the relationship between the presence of FMN and response to part-time occlusion.

Results : Forty-eight amblyopic patients were recruited[FMN(n=15) and no FMN(n=33)]. Patients were stratified by severity of amblyopia at the time of diagnosis (mild=3, moderate=34 and severe=11). Compliance to treatment was comparable between the two groups. 33% of patients with FMN and 30% without FMN were treated with no residual amblyopia (chi squared: p=0.886). The number of months of patching was greater in patients with FMN (27±18.5) versus without FMN (22.4±13.5, p=0.024).

Conclusions : The presence of FMN did not have an impact on treatment compliance. Moreover, occlusion showed efficacy in patients with and without FMN. Interestingly, the duration of treatment in successfully treated amblyopic patients was longer in FMN group than in those without FMN.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.